In March 2025, the company introduced new strategies for any direct-to-client presenting of its Wegovy weight loss drug. The company recognized a whole new pharmacy, identified as NovoCare, which would demand shoppers $499 each month for entry to the drug, below fifty percent the expense of the drug by other pharmaceutical distribution networks.[53